Interleukin-6 targeting therapy in familial Mediterranean fever.
Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Japan. keitafj@gmail.com.
Keita
K
Fujikawa
Kiyoshi
K
Migita
Toshiaki
T
Tsukada
Masataka
M
Umeda
Fumiaki
F
Nonaka
Atsushi
A
Kawakami
Katsumi
K
Eguchi
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003598:Cytoskeletal Proteins / Q000235:genetics; D004252:DNA Mutational Analysis; D010505:Familial Mediterranean Fever / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy; D009154:Mutation; D010641:Phenotype; D000071198:Pyrin; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors* / Q000097:blood; D016896:Treatment Outcome; D055815:Young Adult
D061067:Antibodies, Monoclonal, Humanized; D003598:Cytoskeletal Proteins; D007166:Immunosuppressive Agents; C000604192:MEFV protein, human; D000071198:Pyrin; D019947:Receptors, Interleukin-6; C502936:tocilizumab